HomeTrialNCT07075640
🔬NCT07075640Phase 1RECRUITING

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

Study Summary

The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment24 participants
Primary Completion
Lead SponsorAgios Pharmaceuticals, Inc.
Data Retrieved2026-04-11 02:52:46.815031+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.